BCYC News and Press, Bicycle Therapeutics plc From 03/19/24

2024-03-19 08:19:47 ET More on Fusion Pharmaceuticals Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook Biggest stock movers today: FUSN, NCMI, crypto stocks and more AstraZeneca will buy Fusion Pharmaceuticals for ~$2B Seeking Alpha’s ...

2024-03-12 12:09:42 ET Summary Bicycle Therapeutics plc results from the phase 1/2 Duravelo-1 study, using BT8009 for the treatment of patients with metastatic urothelial carcinoma, expected in the 2nd half of 2024. Data from BT5528 [Bicycle toxin conjugate tech] and BT7480 [Bicyc...

2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...

2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ® ) technology, today announced the acceptance of three abstracts for poster presentation at the America...

2024-02-25 12:00:00 ET More on AstraZeneca, Bristol-Myers, etc. Eli Lilly: Will It Be The First Ever Trillion-Dollar Drug Company? Eli Lilly: Yes, It Is Too Late To Join The Party Eli Lilly: Very Strong Fundamentals, But Market Is Euphoric Phase 3 data for As...

2024-02-21 08:15:02 ET JMP Securities analyst issues UNDERPERFORM recommendation for BCYC on February 21, 2024 08:00AM ET. The previous analyst recommendation was Underperform. BCYC was trading at $22.69 at issue of the analyst recommendation. The overall analyst consens...

2024-02-21 08:15:02 ET Needham analyst issues MARKET OUTPERFORM recommendation for BCYC on February 21, 2024 08:00AM ET. The previous analyst recommendation was Market Outperform. BCYC was trading at $22.69 at issue of the analyst recommendation. The overall analyst cons...

2024-02-20 09:22:48 ET More on Bicycle Therapeutics Circling Back On Bicycle Therapeutics Bicycle Therapeutics gains as former Seagen holder boosts stake Seeking Alpha’s Quant Rating on Bicycle Therapeutics Historical earnings data for Bicycle Therapeu...

Catalyst-rich 2024 with multiple clinical data readouts and updates expected for pipeline and discovery programs Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer now active and recruiting patients BT8009 initial clinical data showed a promising ...